Prospective, single center study to determine whether the current R2* iron mapping method for measuring nigral iron changes in the brain can be significantly improved by using the Quantitative Susceptibility Mapping (QSM) based iron mapping techniques with the goal of validating QSM for potential use in later clinical trials. Subjects with a diagnosis of Parkinson's Disease, Rapid Eye Movement (REM) Sleep Behavior Disorder, and Normal Volunteers who meet the inclusion and exclusion criteria will be eligible for participation in this study.

开始日期2018-08-14

申办/合作机构

Weill Medical College of Cornell University

[+1]

100 项与 11C-PE2I 相关的临床结果

登录后查看更多信息

100 项与 11C-PE2I 相关的转化医学

登录后查看更多信息

100 项与 11C-PE2I 相关的专利（医药）

登录后查看更多信息

项与 11C-PE2I 相关的文献（医药）

2023-05-23·EJNMMI research

Sertraline treatment influences [¹⁸F]FE-PE2I PET imaging for Parkinsonism.

Article

作者: Borghammer, Per ; Hovind, Peter ; Marner, Lisbeth ; Aanerud, Joel ; Justesen, Thomas E H

BACKGROUNDThe dopamine transporter (DaT) PET ligand [¹⁸F]FE-PE2I is used to aid the diagnosis of Parkinson's disease. After encountering four patients with a history of daily sertraline use, who all showed atypical findings on [¹⁸F]FE-PE2I PET, we suspected that the selective serotonin reuptake inhibitor (SSRI), sertraline, might interfere with the results and lead to globally reduced striatal [¹⁸F]FE-PE2I binding due to sertraline's high affinity for DaT.METHODSWe rescanned the four patients with [¹⁸F]FE-PE2I PET after a 5-day sertraline pause. Sertraline plasma concentration was estimated based on body weight and dose, and specific binding ratios (SBR) in caudate nucleus, known to be more preserved in Parkinson's, were used to estimate the effect on tracer binding. Comparison was made to a patient with [¹⁸F]FE-PE2I PET before and after a 7-day Modafinil pause.RESULTSWe found a significant effect of sertraline on caudate nucleus SBR (p = 0.029). The effect showed a linear dose-dependent relationship that corresponds to a reduction in SBR by 0.32 or 0.44 for a 75 kg male or a 65 kg female, respectively, taking a daily dose of 50 mg sertraline.CONCLUSIONSertraline is one of the most commonly used antidepressants and in contrast to other SSRI's, sertraline show high affinity for DaT. We recommend that sertraline treatment is taken into account when patients are undergoing [¹⁸F]FE-PE2I PET especially in patients showing apparent globally reduced PE2I binding. If tolerable, pausing of the sertraline treatment should be considered, especially for doses above 50 mg/day.

2011-05-01·Danish medical bulletin

Evaluation of the superselective radioligand [123I]PE2I for imaging of the dopamine transporter in SPECT.

Review

作者: Ziebell, Morten

Imaging of the dopamine transporter (DAT) with Single Photon Emission Computer Tomography (SPECT) has increasingly been used as a biomarker for the integrity of presynaptic dopaminergic nerve cells in patients with movement disorders. 123-I-labelled N-(3-iodoprop-2E-enyl)-2-β-carbomethoxy-3β-(4-methylphenyl) nortropane, named PE2I, is a relatively new radioligand that has about 10-fold higher in vitro selectivity for the DAT than for the serotonin transporter (SERT) compared to the slightly older but very used and licensed radioligand [123I]FP-CIT (DaTSCAN). Further [123I]PE2I has faster kinetics than [123I]FP-CIT. Because of its fast kinetic properties, quantification of [123I]PE2I binding to DAT is possible using kinetic or graphical analysis following bolus injection of tracer or as a combination of bolus and constant infusion. Based on preliminary bolus trials we have been able to calculate a B/I ratio of [123I]PE2I. This B/I ratio (2.7h) gave rise to steady state conditions and excellent reproducibility. Further, manual delineation of ROI directly on SPECT images performed equally well to a MRI-defined probability map based ROI delineation in terms of intrasubject variability of binding potential of DAT. Finally the in vivo SERT binding in DAT images obtained with [123I]FP-CIT was significant as compared to the [123I]PE2I image. [123I]PE2I is a super selective SPECT DAT radioligand with optimal kinetic properties for accurate quantification of the DAT availability in striatum. Apart from the more laborious B/I design it is currently to be considered the best radioligand for imaging the DAT in the human brain with SPECT.

2011-03-01·Journal of Nuclear Medicine1区 · 医学

Transport of Selected PET Radiotracers by Human P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2): An In Vitro Screening

1区 · 医学

Article

作者: Scherrmann, Jean-Michel ; Kuhnast, Bertrand ; Goutal, Sebastien ; Bottlaender, Michel ; Dolle, Frederic ; Tournier, Nicolas ; Cisternino, Salvatore ; Saba, Wadad ; Valette, Heric ; Peyronneau, Marie-Anne

Radiolabeled compounds used for brain imaging with PET must readily cross the blood-brain barrier (BBB) to reach their target. Efflux transporters at the BBB-P-glycoprotein (P-gp) and the breast cancer resistance protein (BCRP)-could limit their uptake by the brain.METHODSWe developed and validated an in vitro model using MDCKII cells transfected with human multidrug resistance (MDR1) or BCRP genes and assessed the transport of selected PET ligands by the concentration equilibrium technique. The tested compounds included befloxatone, (R,S)-CGP-12177, clorgyline, R-(-)-deprenyl, diprenorphine, DPA-714, fallypride, flumazenil, 2-fluoro-A-85380, LBT-999, loperamide, p-MPPF, PE2I, Pittsburgh compound B (PIB), (R,S)-PK11195, raclopride, R-(+)-verapamil, and WAY-100635. The assays were performed using the nonradioactive form of each compound (ultraviolet high-performance liquid chromatography analysis) and, when available, the (18)F-labeled analogs (γ-counting).RESULTSBefloxatone appeared to be transported solely by BCRP. Loperamide, verapamil, and diprenorphine were the only P-gp substrates. Other ligands were transported by neither P-gp nor BCRP.CONCLUSIONThe present method can readily be used to screen new-compound transport by P-gp or BCRP, even before any radiolabeling. Compounds that were previously thought to be transported by P-gp in rodents, such as p-MPPF, WAY-100635, and flumazenil, cannot be considered substrates of human P-gp. The impact of BCRP and P-gp at the BBB on the transport of befloxatone and diprenorphine in vivo remains to be evaluated with PET.

100 项与 11C-PE2I 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
帕金森病	临床前	瑞典	Karolinska University Hospital	2003-06-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


SNMMI2023	N/A	帕金森病	-	11C-PE2I (Parkinson’s disease patients)	構簾襯廠憲鬱觸簾鏇憲(廠窪獵鬱構襯鏇蓋膚顧) = 觸獵獵網窪齋壓襯壓網積遞衊餘衊窪衊願餘鹽 (鹽糧構糧積鑰鬱製構顧, 8.78) 更多	-	2023-08-28
				11C-PE2I (Healthy controls)	構簾襯廠憲鬱觸簾鏇憲(廠窪獵鬱構襯鏇蓋膚顧) = 範鹽範構廠鑰積簾鬱衊積遞衊餘衊窪衊願餘鹽 (鹽糧構糧積鑰鬱製構顧, 4.95) 更多